Table 1.

Analysis of TP53 mutations in FL and correlation with tumor stage and clinical outcome

Patient no.	Age at diagnosis, y	Genomic no.*	Predicted amino acid no.†	Location	Predicted effect‡	Predicted TP53 function‡	Disease stage at presentation	Initial treatment	PFS, mo	OS, y
1	45	g.13216 T>A	p.H179Q	Exon 5	Missense	Nonfunctional	IIe	Single-agent chemotherapy	10	7.7
2	Not known	g.14028 A>G	p.Y234C	Exon 7	Missense	Nonfunctional	Not known	Multiagent chemotherapy	53	4.5
3	47	g.14057 G>A	p.G244S	Exon 7	Missense	Nonfunctional	III	Multiagent chemotherapy radiotherapy	11	5.0
4	71	g.14060 G>A	p.G245S	Exon 7	Missense	Nonfunctional	II	Radiotherapy	21	11.9
5	64	g.14060 G>T	p.G245C	Exon 7	Missense	Nonfunctional	IV	Expectant management	24	9.8
6	59	g.14061 G>T	p.G245V	Exon 7	Missense	Nonfunctional	IV	Multiagent chemotherapy	4	0.5
7	65	g.14111 T>G	NA	Intron 7	Splice site	Splice	III	Multiagent chemotherapy	11	0.9
8	78	g.14486 C>T	p.R273C	Exon 8	Missense	Nonfunctional	III	Multiagent chemotherapy	12	7.7
9	53	g.14487 G>A	p.R273H	Exon 8	Missense	Nonfunctional	III	Radiotherapy	25	4.4
10	63	g.14487 G>A	p.R273H	Exon 8	Missense	Nonfunctional	II	Multiagent chemotherapy	16	2.3
11	63	g.14513 C>T	p.R282W	Exon 8	Missense	Nonfunctional	IV	Multiagent chemotherapy	15	2.0
12	75	g.14517 G>A	p.R283H	Exon 8	Missense	Functional	IV	Multiagent chemotherapy	15	1.3

PFS indicates progression-free survival; OS, overall survival; and NA, not applicable.

^*Genomic numbers refer to reference sequence U94788.

^†Predicted amino acid numbers refer to a translation of NM000546.

^‡Predicted structural and functional characteristics of the mutations were obtained from the mutation validation tool of the IARC TP53 Mutation Database.